Addressing medicinal drug manufacturers

To execute No. Pr-1452 instructions of the President of the Russian Federation of 27.07.2016 the Federal Antimonopoly Service summed up the results of the first stage of international comparative analysis of prices for medicines circulating on the domestic market. FAS analyzed prices for pharmaceuticals used to treat cost-intensive seven nosologies, centrally purchased by the Ministry of Health Care.

An analysis exposed several drugs, prices for which in Russia were higher than the minimum prices in some countries, particular, reference countries for Russia.

For all exposed cases of registered in Russia maximum ex-works producer prices exceeding the minimum prices in foreign countries, included in the list of reference countries, FAS is carrying out an investigation, on the basis of which the relevant prices will be abolished should it be confirmed that incorrect data were submitted to register prices (Clause 25 of the Rules for state registration and re-registration of maximum ex-works prices fixed by manufacturers for the medicinal drugs included in the list of vital and essential drugs, approved by No.865 Decree of the Government of the Russian Federation of 29.10.2010 (the Rules for price registration)).

At the same time FAS proposed to the owners or holders of registration certificates of the relevant drugs by 20 October 2016 to take advantage of the right for filing applications to reduce registered maximum ex-works producer prices, under Clause 23 of the Rules for price registration.

FAS continues analyzing prices for other drugs purchased with funding from the federal budget.